The UAE Approves a Gene Therapy for Spinal Muscular Atrophy Patients: A Global Pioneer
The Emirates Drug Authority has announced the approval of a new gene therapy known as “Itvisma,” making the UAE the second country in the world to offer this type of treatment for patients suffering from spinal muscular atrophy. This decision marks a significant achievement, demonstrating the UAE’s commitment to providing the latest gene therapies for patients and enhancing the capabilities of the country’s healthcare system in evaluating and approving advanced medications according to the highest scientific standards. This initiative enables patients to access innovative treatment options that significantly improve their quality of life.
The Role of the UAE in Providing Gene Therapies
The Emirates Drug Authority confirmed that obtaining regulatory approval for the “Itvisma” medication is a clear indicator of the efficiency of the country’s healthcare system. In this context, Dr. Fatima Al Kaabi, the General Director of the Authority, stated: “This treatment is based on clinical study results that showed a significant improvement in patients’ motor abilities, with the sustainability of these improvements over the long term.”
Al Kaabi also expressed pride that the UAE has chosen to approve this treatment, affirming that it reflects the country’s commitment to adopting the best modern pharmaceutical technologies and enhances international confidence in the country’s regulatory model.
Benefits of “Itvisma” Treatment
The “Itvisma” treatment utilizes a viral vector and targets spinal muscular atrophy patients aged two and older. With this step, the UAE is charting a new course toward providing advanced gene therapies that may enhance treatment effectiveness for men, women, and children, contributing to an improved quality of life for many patients.
The Future of Medical Innovation in the UAE
The Emirates Drug Authority announces its ongoing support for medical innovation and the adoption of modern gene therapies as part of the country’s vision to build a world-class healthcare system based on knowledge, efficiency, and sustainability. The approval of “Itvisma” is part of its strategy to provide innovative and high-quality medications for patients, enhancing the UAE’s position as a regional hub for pharmaceutical innovation.
Reliance on these advanced technologies is not just a step toward addressing rare diseases like spinal muscular atrophy; it represents an evolution that enhances the UAE’s capabilities in the pharmaceutical industry and supports its efforts to establish itself as a leader in global health.